Market Snapshot: Zaltrap Changes Cost-Benefit Expectations For New Colon Cancer Drugs
Lilly’s Cyramza, Boehringer Ingelheim’s Vargatef and Taiho’s TAS-102 will join an increasingly crowded and price sensitive market in metastatic colorectal cancer in the coming years.
You may also be interested in...
Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.
Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.
Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.